Contribute Try STAT+ Today

A prominent advocacy group is asking Gilead Sciences (GILD) to relinquish a valuable voucher that came with Food and Drug Administration approval of its remdesivir treatment for Covid-19, arguing the voucher is “an entirely unnecessary and an inappropriate incentive” for a drug that has “limited” effectiveness and is already generating huge profits.

In a letter to Gilead, Public Citizen maintained the priority review voucher — which the FDA awarded for developing a drug that posed a “material threat” to public health — offers the company an undeserved windfall. Vouchers are granted to encourage certain drug development, and companies can receive accelerated FDA review time for another drug or sell them to other companies, sometimes for $100 million or more.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy